Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Dysregulation: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| PI3K/AKT/mTOR Signaling | associated_with | pathway | 0.85 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| Proposed experiment from debate on Perivascular spaces and glymphatic | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $240,000 |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Proposed experiment from debate on Perivascular spaces and glymphatic | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Vascular Contributions to Alzheimer Disease and Mixed Pathology | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Aquaporin-4 in glymphatic system, and its implication for central nervous system [PMID:36796590] | Peng S, Liu J, Liang C, Yang L, Wang G | Neurobiol Dis | 2023 | 2 |
| Uncommon inflammatory/immune-related myelopathies. [PMID:34715593] | Valencia-Sanchez C, Flanagan EP | J Neuroimmunol | 2021 | 2 |
| Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressu [PMID:31959516] | Reeves BC, Karimy JK, Kundishora AJ, Mes | Trends Mol Med | 2020 | 1 |
| Inebilizumab-cdon. [PMID:32936251] | Unknown | American journal of health-sys | 2020 | 1 |
| The glymphatic pathway in neurological disorders. [PMID:30353860] | Rasmussen MK, Mestre H, Nedergaard M | Lancet Neurol | 2018 | 1 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955] | Qi F, Lennon VA, Zhao S, Guo Y, Ding H e | J Clin Invest | 2026 | 0 |
| Opioid-induced transcriptional reprogramming of cerebrospinal fluid immune cells [PMID:41674808] | Acharya A, Ambikan AT, Neogi U, Lamberty | Res Sq | 2026 | 0 |
| Siah2 is a lipid-mediated metabolic sensor in adipose tissue macrophage. [PMID:41690475] | Dang TN, Ghosh B, Panta PR, Taylor JM, K | J Lipid Res | 2026 | 0 |
| Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198] | Bennett JL, Bhattacharyya S, Zabeti A, L | Mult Scler | 2026 | 0 |
| Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387] | Elosua-Bayés I, Cobo-Calvo A | Rev Neurol (Paris) | 2026 | 0 |
| Multimodal MR Imaging Reveals the Mechanisms of Post-Cardiac-Arrest Brain edema: [PMID:41933462] | Tan Y, Ye H, Ge Q, Wang P, Liu Z et al. | J Magn Reson Imaging | 2026 | 0 |
| Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816] | Jiang X, Chen J, Wen Y, Yuan L, Zhang J | The Journal of international m | 2026 | 0 |
| Astragaloside IV alleviates post-traumatic cytotoxic edema via inhibition of AQP [PMID:41916121] | Shen W, Jiang C, Liu X, Wang D, Li G, Hu | Phytomedicine : international | 2026 | 0 |
| Glymphatic System Dysfunction in Central Nervous System Diseases. [PMID:41792880] | Zahran A, Abu-Khazneh O, Bdair M, Hajjeh | CNS neuroscience & therapeutic | 2026 | 0 |
| The postnatal expression of transcripts and proteins in the corpus callosum, as [PMID:41915271] | Mayo F, González-Vinceiro L, Hiraldo-Gon | Journal of physiology and bioc | 2026 | 0 |
| Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD [PMID:41921124] | Tournier A, Gavoille A, Pique J, Levraut | Neurology | 2026 | 0 |
| Mapping the Brain's Glymphatic System. [PMID:41751308] | Voumvourakis K, Thomaidis NS, Tsiodras S | Biomedicines | 2026 | 0 |
| Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seroneg [PMID:41909718] | Cao X, Qin D, Wang B, Wang C, Guo S | Frontiers in immunology | 2026 | 0 |
| Physical exercise as a non-pharmacological strategy to enhance glymphatic functi [PMID:41676384] | Ghayourvahdat A, Azimizonuzi H, Ahmed M | IBRO neuroscience reports | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Dysregulation in their description or question text
Score: 0.680 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The molecular mechanism underlying AQP4-mediated neuroinflammation centers on the
Score: 0.676 · alzheimers · 2026-04-28
Alzheimer's pathology disrupts circadian PER1/2 and BMAL1 rhythms in hippocampal neurons. Gamma entrainment, particularl
Score: 0.666 · neurodegeneration · 2026-04-07
## Mechanistic Overview TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence starts from the claim that mod
Score: 0.666 · neurodegeneration · 2026-04-16
## Mechanistic Overview LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Suppression starts
Score: 0.625 · unknown disease · 2026-04-26
Intron-retained GBA isoform sequesters neuronal RBPs (FMRP, HuR, TDP-43) that normally bind to wild-type GBA mRNA 3′UTR
Score: 0.620 · neurodegeneration · 2026-04-21
## Mechanistic Overview Synaptic RNA Metabolism Dysregulation starts from the claim that modulating TARDBP within the di
Score: 0.620 · neurodegeneration · 2026-04-22
## Mechanistic Overview Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD starts from the claim
Score: 0.612 · neurodegeneration · 2026-04-02
## Mechanistic Overview Complement-Mediated Synaptic Pruning Dysregulation starts from the claim that modulating C1QA wi
Score: 0.604 · neurodegeneration · 2026-04-28
The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD patholog
Score: 0.600 · neurodegeneration · 2026-04-29
TDP-43 stress-granule entry and liquid-liquid phase separation may transition from reversible condensates into pathologi
Score: 0.580 · neurodegeneration · 2026-04-22
## Mechanistic Overview H5: Complement Dysregulation Drives Synapse Loss via Senescent APOE4 Astrocytes starts from the
Score: 0.580 · neurodegeneration · 2026-04-26
Aryl hydrocarbon receptor (AhR), expressed in microglia, astrocytes, and neurons, normally ligates tryptophan catabolite
Score: 0.570 · neurodegeneration · 2026-04-25
REST Complex Dysregulation as Master Epigenetic Switch: The RE1-silencing transcription factor (REST) has been proposed
Score: 0.520 · neurodegeneration · 2026-04-21
## Mechanistic Overview miR-143/145 Cluster Dysregulation Derepresses P2RY12 Transcription starts from the claim that mo
Score: 0.507 · developmental-neurobiology · 2026-04-21
## Mechanistic Overview Epigenetic Dysregulation of APOE Microglial Expression starts from the claim that modulating APO